Lilly cancer R&D chief Bilenker quits, handing reins to deputy

Eli Lilly’s cancer R&D chief Josh Bilenker, M.D., is hitting the exit. His departure comes two years after the Big Pharma ponied up $8 billion for Bilenker’s startup, Loxo Oncology, and one year after it combined the oncology team at Lilly Research Laboratories with the Loxo team—and put Bilenker and two other Loxo executives in charge.